Editorial Comment on: Low-Activity V89L Variant in SRD5A2 Is Associated with Aggressive Prostate Cancer Risk: An Explanation for the Adverse Effects Observed in Chemoprevention Trials Using 5-Alpha-Reductase Inhibitors
pages 1088 - 1089
Jump to
Viewing articles 31-40 of 83
Risk-Adjusted Analysis of Positive Surgical Margins Following Laparoscopic and Retropubic Radical Prostatectomy
13 December 2006 | pages 1090 - 1096
Prostate Biopsies Guided by Three-Dimensional Real-Time (4-D) Transrectal Ultrasonography on a Phantom: Comparative Study versus Two-Dimensional Transrectal Ultrasound-Guided Biopsies
27 November 2006 | pages 1097 - 1105
Impact of Multimodal Treatment on Survival in Patients with Metastatic Urothelial Cancer
6 March 2007 | pages 1106 - 1114
pages 1113 - 1114
Weekly Paclitaxel and Carboplatin against Advanced Transitional Cell Cancer after Failure of a Platinum-Based Regimen
5 April 2007 | pages 1115 - 1122
Long-Term Intravesical Adjuvant Chemotherapy Further Reduces Recurrence Rate Compared with Short-Term Intravesical Chemotherapy and Short-Term Therapy with Bacillus Calmette-Guérin (BCG) in Patients with Non–Muscle-Invasive Bladder Carcinoma
12 March 2007 | pages 1123 - 1130
Synergy of Interferon-α and 5-Fluorouracil in Human Renal Cell Carcinoma Requires p53 Activity
22 January 2007 | pages 1131 - 1139
Viewing articles 31-40 of 83